Innovation
Innovation
Innovation supports the development of cultures and systems that evolve to meet new challenges facing healthcare systems and biomedical advances. The UK’s ecosystem encourages innovation through robust partnership working, strong science base, comfortable business environment and the NHS system itself.
Innovation
The NHS has a long history of being at the forefront of developing innovative new treatments to improve patient care and outcomes.
Industry, academia, government, the NHS, and charity health funders have co-designed the future of the sector with a shared vision and continued partnership working in the sector. Leading universities, a skilled workforce and a track record in delivering Nobel Prize winning science. The UK also has The award winning NHS Innovation Accelerator, or NIA, which supports uptake and spread of promising, impactful innovations across England’s NHS.
The NHS Accelerated Access Collaborative is a great example of bringing together industry, government, regulators,
patients and the NHS to remove barriers and accelerate the introduction of ground breaking new treatments and
diagnostics which can transform care.
Innovation is a key element of the 2019 NHS Long Term Plan. Patients benefit enormously from research andinnovation, with breakthroughs enabling prevention of ill-health, earlier diagnosis, more effective treatments, better outcomes and faster recovery. Innovations created through the NHS can be shared with overseas partners and adapted to their local contexts. The NHS accelerates innovation that can be shared to help overseas partners to understand the creation of a national innovation infrastructure.
The NHS and UK Private sector are able to provide:
- Strategy support for the creation of a national innovation infrastructure
- Consultancy on development of national and local strategies to foster innovation and encourage diffusion
- Genomics services –genomics sequencing services, research and development collaborations and personalisedmedicine services –embedding genomics into Primary care –counselling services
- Consultancy to support creation of sustainable healthcare systems –carbon neutral health services
- Turning research into clinical breakthroughs
Innovation
Organisations that specialise in innovation
→
→
→
→
→
→
→
→
→
→
Innovation
Case study: Cell and Gene Therapy Catapult
Whether you’re at the very start of your research, looking to manufacture therapies, or need regulatory support, we can help.
We have the infrastructure and a team of specialists across the cell and gene therapy life cycle, who will work with you when you need us, to enable you to get the best possible results. We have a range of approaches that can help tackle the challenges you might face in the development of cell and gene therapies. We’ll work with you to accelerate your projects, helping your cell and gene therapies to be safer, more effective, scalable and affordable. We make it our job to stay at the forefront of the latest innovations in cell and gene therapies, so that we’re ready to help, whenever you might need us.
- UK companies have received £2.5bn+ investment
- There are 90+ advanced therapy developers in the UK
- Of UK ATMP developers 69% have collaborated with CGT Catapult
- There are active clinical trials in 2019, compared to 85 in 2018
- There has been a 45% growth in UK clinical trials
- There are 3,000+ jobs compared to 540 in 2012
- There are 26 GMP facilities compared to 11 in 2012
- There has been a 136% increase in the number of GMP manufacturing facilities
- The 7,700m2 CGT Catapult manufacturing centre opened in 2018.